Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00771615 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
NCT00771615 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 469 participants.
The verdict
NCT00771615, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
Study Summary
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
Interventions
- BIOLOGICAL GSK A/turkey H5N1 Influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2008-10-16 |
| Est. Completion | 2009-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00771615
The ClinicalTrials.gov registry entry for NCT00771615 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 469 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK A/turkey H5N1 Influenza vaccine is the first listed.
NCT00771615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00771615 about?
NCT00771615 is a clinical study titled "Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years". The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
What is the current status of trial NCT00771615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2008-10-16. Estimated completion is 2009-12-04.
What interventions are being tested in trial NCT00771615?
The interventions under investigation include: GSK A/turkey H5N1 Influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00771615?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.